ArticlePharmaceutical research2026
Melt-Extruded Paclitaxel Nanocrystal-Loaded Sutures for Sustained Local Drug Delivery.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop biodegradable poly(lactic‑co‑glycolic acid) (PLGA) sutures loaded with paclitaxel (PTX) nanocrystals for sustained local drug delivery and to systematically evaluate their physicochemical, mechanical, and drug‑release properties.
methodsPTX nanocrystals were prepared via wet media milling, yielding particles with a Z‑average size of 278.33 nm and a polydispersity index of 0.207. The nanocrystals were incorporated into PLGA sutures using a solvent‑free melt extrusion process followed by fiber drawing. Scanning electron microscopy was used to assess nanocrystal dispersion and fiber morphology, while wide‑angle X‑ray scattering evaluated PTX crystallinity and crystal orientation within the fibers. Mechanical properties were characterized by tensile testing. In vitro studies were conducted to assess fi ber shrinkage and PTX release behavior.
resultsScanning electron microscopy confirmed homogeneous dispersion of PTX nanocrystals throughout the PLGA matrix, and wide‑angle X‑ray scattering demonstrated retention of PTX crystallinity with partial crystal orientation induced by fiber drawing. Molecular alignment of PLGA chains during stretching significantly enhanced mechanical performance, with stretched fibers exhibiting a tensile strength of 78.70 ± 11.50 MPa compared to 59.60 ± 2.50 MPa for unstretched polymer rods. Substantial fiber shrinkage was observed during in vitro studies; however, incorporation of PEG 8000 reduced shrinkage from 62% to 24%, but also reduced tensile strength to 40.33 ± 6.00 MPa. Drug‑release studies revealed a biphasic profile characterized by an initial lag phase followed by sustained PTX release, reaching approximately 60% cumulative release over 63 days.
conclusionThese findings support the feasibility of melt‑extruded, drug‑loaded PLGA sutures as a platform for sustained local drug delivery.
Indexed as
Identifiers
41927961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.